platform

drug

Anavex Life Sciences Corporation

wait

Seems crazy to me to unjust approvals that are going on while we wait on legitimate results!!!

But why wait 3 years with that when Anavex 50mg dose is likely better! !

So, if one waits months for an answer and then has to resubmit to another journal it can hold things up.

This is a shitshow till data is presented.

loss

but  losses  and  disappointment  with  Missling.

$AVXL Took my $250 loss and Got out guys too much noise not enough action.

but was faked by the move and held them to expiration and had to book a loss of $19,000.

shareholder

The krout has proven to be an a hole toward shareholders.

Missling is a greedy pig, doesnt see the bad he does by delaying intentionally, not only to shareholders,

i am telling for years that we need to fire that shitty guy just here to full his pockets without any consideration for his shareholders.

.this guy doesnt respect his shareholders and he must be sue for that.

$AVXL fire Missling, he has been here 9 years and done nothing to drive shareholder value other than BS hype

$AVXL why does the company not believe they are beholden to their shareholders?

$AVXL Unfortunately the Investorshub AVXL board has deteriorated to the point that it is basically a board consisting of almost entirely FUD with almost more bashers than true shareholders.

Messling is grossly deficient in anticipating the expectations of shareholders and the market.

$AVXL as corporate shareholder, I have sent an email on dec. 21st and a friendly reminder yesterday to IR - no response yet !!

One hand he says he care for shareholder value, on other hand he is purposely not sharing updates.

shareprice

$AVXL missling next time should change a few letters when hiring and SP will improve: from FDA to FBI former employee.

$AVXL Every time Missling speaks, the SP tanks…..amateurish communication, unbelievable.

It&#39;s stupid, it wastes time (and $$$) and it leaves the company vulnerable with a supressed SP.

Based on Rett alone, SP is well under 100$, sorry to bust your ballown,but please try to stay realist and keep a little credibility!

$AVXL The sp is wrong there must be a glitch

$AVXL not that i am happy with the SP overall

$AVXL Until you realize that and admit that the presenter screwed up in rushing the presentation the SP will stay where it’s at

$AVXL wandering when we will cross ANVS SP ;) 
never again!!!!

$AVXL we didnt cross ANVS SP yet, no good haha!

show

Take your money from this shit show and deposit in your bank account.

What an absolute unregulated criminal shit show this market has become.

Missling shows poor judgement and is not suited to be ceo.

SHOWS THE EXTREME WEAKNESS AND  DISTRESS THE STOCK IS UNDER.

but need more time to evaluate and announce a conference call for Monday instead we have a shit show.

The greatest part of it was the team work on this platform, including investors from a number of other Bio counters.

- Timo grimmer is in the team 
- All endpoints of the clinical trial were reached 
 
I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

we have a drug, even many drugs, good for so many indications,  to become a giant pharma, we are about to get billions in revenues.

$AVXL The improvements in the drug arm cannot be lucky. .

I&#39;m looking forward to seeing the long term AD data on ANVS and have the feeling it&#39;s going to end up being the best in class AD treatment as well.

Do not listen to any FUD this drug is the real deal.

$AVXL amazing to see the actual benefits to people and their families of this “miracle drug” as they call it

$AVXL Dr. Perry said we have a legendary drug which actually reverses AD and is safe unlike Adulhelm.

business-result

Anavex&#39;s A2-73 Blarcamesine&#39;s trial results on 2 previously completed adult phase-3 trials were highly successful.

But the company actually has never seen before wonderful results.

If results hold up, the stock will achieve massive gains.

The results were excellent on the 2 completed adult trials, and because the 3rd trial is pediatric and early on the disease, they are expected to perform even better.

Alzheimer&#39;s is the most valuable and most difficult indication and most desired lately..  and only Anavex really has some great results with a great safety record. .

The  sava  results  trounce  you  guys  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

Sava has potential and the phase 3 results will show the truth.

trial

$AVXL amazing  avxl  still  in  singke  digits  after  a  supposedly  amazing  “pivotal”  trial  readout  🤦🏻‍♂️🤦🏻‍♂️🤦🏻‍♂️😂😂😂

$AVXL The trial met both co-primary and secondary endpoints showing statistically significant reduction of clinical decline as measured by those endpoints.

$AVXL Australia trial data meets the gold standard.

2-73 has orphan designation for Rett which combined with the multiple Rett trials and it very good safety record should make it a great candidate for AA.

This company has yet to fail to meet endpoints on any trial and the thousands of papers on the MOA  eliminates fraud with science, and the company is in great fiscal shape so no shenanigans there.

patient

It can be shown that treatment bringing back independence is less costly than the nursing homes and medical staff.

$AVXL This may show why Anavex is definitely on the right path by using patients personal genetics to determine dosage.

Many claim him to be selfish and unconcerned with others, I see a different Missling, with humility and a deep concern for patients who are suffering.

Half the patients improved over baseline over 1 year.

Blarcamesine’s Phase III clinical trials show similar levels of significant improvement in communication and interaction, as patients had statistically significant improvement in the RSBQ primary endpoint of 72.2% compared to 38.5% on placebo. .

And better still for just those 85% carrying the normal SigmaR1 gene as well as for APOE2 and 3 patients.

new clinical trial results show great promise for treating early Alzheimer’s, giving renewed hope for effective treatments.

Anavex has over 760 patients that have taken it without any significant issues. .

Cassava Sciences Inc

action

The day to day price action of this limp dick is more painful to watch than slugs breeding.

$SAVA , this daily one way action is depressing.

Zero confidence in management based on both recent actions and historical issues with the FDA. 2.

$SAVA We may get frustrated with volatility, manipulation, and irregular daily price action

price

This is sickening that these crooks can manipulate the price like this. !!!

He invites shorts to destroy stock price.. pathetic!

Some had to drop in price a little first!

new employee mr. cook must be pissed as this is lower price than the shares he got it for.

All.u did was dilute the pps 
..and release to prs to kill the stock price and momentum  
 You did so well..you fxuking scumbag.

I hate the stock price runup leading to an announcement.

data

- 
$AVXL in comparison, boring as hell - whenever Missling talks people fall asleep and holding back data and further readouts without any logical explanation are red flags -

$SAVA 
Pyggie here was bullish a few days ago, folded like a pussy because he can’t read data, and now spews FUD, like a spoiled child, because he’s worried he may have paper-handed a monster.

but offer only the “opinion” that there was “possible data manipulation.”

$SAVA longtime biotech investor and my honest experience when a CEO promises good data and there is a long waiting period = not good.

Sentiment matters in this game, and unfortunately, this company has been drug through the mud for so long that good data might just get overlooked.

$SAVA The ironic and sad thing is that this ticker has been abused and manipulated so badly that even if it triples on upcoming data release it still won&#39;t come close to ATH achieved on much less evidence of safety and efficacy.

The CEO belongs in jail with all this pump and dump stock manipulation and data manipulation

just annoying we all get so worked up and insulting when we, the retail investor, can neither move Remi to release data early or in truth, move the SP by buying or selling a few hundred shares.

$SAVA dumb management causing longs to lose confidence, you dont change the date of data release every few weeks, just give a date when you are certain and stick with that, its that simple

BIIB with a 27% chance of no decline - so bad, how can they even publish data like that.

however, if you are a family member of Alz patient think about how fatiguing emotionally and financially it is to change diapers, have your name forgotten, or even have to take a license away from an otherwise healthy person.

but your day will come when you will pay back way more than the damage you have caused and the lives you have threatened from being treated for a debilitating disease.

$ALZN $ATHA $ORMP $SAVA $SPRC yes then go back to your scam board clown no need to trap others in this scam .. we know what value SAVA brings to their AD patients

Lecanemab approved - IV  infusion..increased infection risk, inconvenient for patients with MD&#39;s fully aware 
of side effects: brain swelling and bleeding. 2.

Eventually, the  
AD patient is unable to perform daily functions.

But the monoclonal antibody treatment also carries risks of brain swelling and bleeding.

$BIIB - lied and tried to push their bad drug Aduhelm on unsuspecting patients (one of which is a family member of mine).

3 deaths in 1900 trial patients.. how many deaths is our FDA going to inflict on millions of folks who are supposed to take this death drugs that also happen to have near-zero efficacy?? SMH

Avxl, not good they didn&#39;t have an agreement in place “plan for approval“ before they started the test fase 2b 500 patients.

$SAVA It&#39;s not only CRUEL for anyone to be prescribing any of these MABs for AD patients, it&#39;s impractical for both patients and the healthcare system in general.

application

$SAVA Words  to  to  ignorant,  never  hype  a  employee  from  fda,  shady  shiat! 🤡🤡🤡😂😂😂

It doesn&#39;t matter if drugs for terminal illnesses, have been approved after 6 months, because there is endless manipulation here, and this waiting game is based on either FDA approval or denial based on corruption at the agency?

This is such crap with the FDA my Father died a year ago from it

$BIIB $SAVA You would need uncommon patience to not be crazy mad at the system for this shenanigan approval process and decision from the FDA.

Idiots with no respect for integrity continues  to run 
wild within the FDA.

$SAVA once again we got fu*ked by the evil BIIB + FDA.

$SAVA THIS is how corrupt our FDA and state medical boards are.

$BIIB $SAVA  
I tell ya why - FDA is corrupt deep in its root, period!

$SAVA I’m
Itching to buy again it’s looking good this is such and opportunity Buy buy buy my reception is just as shoddy as the Shorts and the Fudsters on this platform

Again with respect to all the good attorneys on this platform.

$SAVA Guys this is a SAVA platform let’s keep it that way 
Thank you

That’s a lot of money to invest multiple times on a promising treatment 🚀

This is the ONLY drug in HISTORY to improve cognition after 12 months.

$SAVA A safe drug that impacts both neurodegeneration and neuroinflammation is going to have potential treating other CNS diseases.

Proper stock and proper drug doesn&#39;t smell like a scam.

Deeply appreciative of the treatment that SAVA is working to deliver,

$SAVA this is going to be game changer and first drug to give some relief to AD patients … and will make $BIIB poison AD pills an obsolete

I’m holding long term because I truly believe this is the first effective Alz treatment to date.

And, make no mistake, the result are impressive.

It is the best results that have been seen in AD.

This could be huge in eliminating artificial FUD against the top-line results.

$SAVA Market is moving higher as SAVA is expecting data results.

Anavex is late like the sun comes up and still produces great results.

MOST IMPORTANTLY, THE RESULTS MUST HAVE BEEN GOOD AND PROMISING at each snapshot that leads Remi to use the word &quot;Thrilled&quot; in Dec 6 PR.

Data tells me no safety issues, with a possible large therapeutic window.

Then they dropped the “good” totally “not disappointing” data that Remi was so “Thrilled” about.

This will go beyond parabolic on good data … literally no shares out there unless they offer new ones … $MDGL $VKTX $SLS $SAVA

SAVA data gets analyzed by multiple different labs and shows its cognition improvement in mild AD cases, safe and well-tolerated

$SAVA I love not being able to hold $28 off data that will keep it pinned here until 2024.

but the data to date would predict continued efficacy that will be nigh on impossible to ignore.

$SAVA Institutional buying says data is good!! !

I’ll keep buying until data comes out…

Excited for the next data unveiling….bring it on!

$SAVA “Treatment also eased depression and dementia-related behaviors in patients, two exploratory trial goals, and simufilam was found to be safe and well tolerated.”

This will bring in billions of revenue and it will make the life quality longer for AD patients.

This sub-set of patients improved -4.96 mean points on ADAS-Cog from baseline to month 12.

CURING LEUKEMIA isn&#39;t a fly by night thing with Gamma T Cells and they already have ONE COMPLETE RESPONSE curing someone in Stage 4 nonresponsive to other treatments!

The high number of the patients that went into CMS (which is 80% complete) is reassuring.

but reverses cognitive decline and improves quality of life for the patient AND the FAMILY!

but mostly new hope for all the families and patients with AZ.

Testing still continues, so in my way of thinking the real-world results in patients must be nothing short of excellent.

Xeris Biopharma Holdings Inc

manipulation

$XERS  This stock has become totally distorted by Wall Street manipulators!

In fact its just market manipulation by  shorts and rich assholes who use stocks like slot machines.

$XERS This stock is heavily MANIPULATED by a &quot;Gang of Shortsellers&quot; and has nothing to do with a fair market price!

It is so obvious this is being systematically walked down (manipulated) and has nothing to do with the Company itself, products, or the overall market.

Just goes to show how badly manipulated this is.

The manipulation of these criminals is unbelievable.

This Share Price is still 
 
Crazy  
 
Stupid  
 
Low. Cheers!

$XERS  This share price is crazy stupid low.

You’d think Paul would have some shame being below their price.

What is most disappointing about XERS, except for the collapse in stock price, is the failure of management to do much of anything to encourage retail or institutional investors to continue to have the confidence in management of the company or its future.

I think price targets are fake… there compensated to make targets IMO.

suck

Unfortunately, the mkt sucks now and that’s reflected in sp.

The whole market sucks and this has been unjustly hammered.

$XERS this is so fucked up its unbelievable.

Invested a lot of money , and realizing we are fucked.

market

What a crappy market! Hopefully next week will be better:)

$XERS A bad market must admit it is really a bad day.

$XERS A 10+ cent drop when you only have 14 of those until 0 ahead of all that gobbledygook fundamental longs are spouting is not a great sign of market confidence.

$XERS market on a year and this lame duck is flat or sinking

but unfortunately, in this market, not cheap either, and even less an outright buy without a very very strong conviction.

Market hinting something is terribly wrong with this company.

revenue

$XERS High risk is an understatement with XERS, weak drug lineup, weak pipeline, revenue grow slowing, cash burn increasing and worse than weak management should tell you to stay away.

Nothing positive, revenue continues to slow, spending increasing, generics coming, recorlev under performing and most important, incompetent management! !

Personally, I think this is very conservative, and comes in below the Strongbridge &quot;Low Case&quot; from page 87 of the merger prospectus because it comes out to $172M annual revenue in 2023 compared to $216M revenue on the prospectus.

Revenues are slowing, expenses are increasing, tech is marginal, patents will be expiring, pipeline is horrible and management is horrible.

but also very disappointing that my EV charger stocks have $Billion mkt caps with less than $50M revenue and years from cash flow positive and yet.

Not only are the current drugs low revenue producers and the pipeline is horrible.

.WS not impressed with 3 low revenue drugs and weak pipeline.

A levothyroxine formulation that looks positive (most commonly prescribed drug) A full proven technology platform to deliver hard to administer drugs by a simple injection.

$XERS more importantly for me: second product that proves to SC platform and suspension works!

Two other drugs, each growing revenue steadily.

Two (2) other drugs, each growing revenue steadily.

We have other amazing drugs, Recorlev, Gvoke and more including some drugs yet to be approved.

That said, I fully expect continuing  script and revenue growth, upcoming cashflow breakeven and some nice juicy licensing deals to resolve that in the months ahead.

There is so much good news here, growing revenue, a stable base, conservative management, and connections to big pharma.

product

$XERS their primary product increases 9% week to week sales with an overall trend that&#39;s incredible.

$XERS I like their products and the inject opportunity with Horizon Tepezza is huge I wish they weren&#39;t acquired so they can keep a focus on that.

Earnings are growing and there could be great news any day from a variety of sources, whether a collab exercise of option, new product collab, royalty pmt, etc.

More important is that they grow Recorlev&#39;s revenue at high(er) speed, and continue to gain market share with Gvoke without product price drop.

Revenue exploding on the upside with
their 4 products.

Even if they have more short term gains coming soon, we know the Gvoke product will gain share back due to the more pleasant experience. Patience.

Gvoke is the best and easiest product out there.

Products have been approved and much more is coming, wait and relax.

For a tiny company like xeris to go toe to toe with lilly and grow share shows they have the best product.

$XERS Truly so strange, everything Xeris had in its programme has been met, briefly 3 FDA approved products, collaborations with major pharmacies and much, much more.

$XERS Good market yesterday, looking good today and good old XERS continues in the tank!!

but all of last week, in the middle of heavy market turmoil where we normally go down heavily, we stayed up and rose. Why?

Plenty of small caps were brought to lows (and thus made good buys) before starting recovery in this bear market, $ADMA, $ARAY, $PRTK, $CDTX, they all have turned or are turning around cause there is deep value and a clear path to profitability.

Top Stocks matching your search for "platform treatment"

Click Learn More to know about Stock Advisor's top picks. We've 3x'd the S&P 500 over the last 20 years.

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Dec, 2, 2022

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Jan, 17, 2023

Jan, 3, 2023

XERS

Xeris Biopharma Holdings Inc

15.52%

$1.16 - $1.34

Mar, 4, 2023

Oct, 20, 2022

AVXL

Anavex Life Sciences Corporation

-22.55%

$11.75 - $9.10

Dec, 2, 2022

SAVA

Cassava Sciences Inc

-13.96%

$29.88 - $25.71

Jan, 17, 2023

Jan, 3, 2023

Dec, 13, 2022

XERS

Xeris Biopharma Holdings Inc

15.52%

$1.16 - $1.34

Mar, 4, 2023

Oct, 20, 2022